YDES
YD Bio Limited Ordinary Shares
$5.73
+0.96
(+20.13%)
Mkt Cap
337.87M
Volume
653,272
52W Range
1.7-22
Sector
Healthcare
Beta
-0.12
EPS (TTM)
-0.99 USD
P/E Ratio
-101.58
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$0.63
Overvalued
strong signal
655.9% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 596,817 | 510,360 | 350,131 | 0 | 0 | 0 |
| Net Income | (8.31M) | (1.41M) | 13,560 | 3.79M | 8.70M | (2.54M) |
| EPS | -0.12 | -0.56 | 0.00 | 0.41 | 0.59 | -0.17 |
| Free Cash Flow | (8.04M) | (4.75M) | (55,947) | (3.02M) | (688,420) | (253,620) |
| FCF / Share | -0.12 | -1.15 | -0.00 | -0.33 | -0.05 | -0.02 |
| Operating CF | (6.60M) | (1.84M) | (55,657) | (3.02M) | (688,415) | (253,625) |
| Total Assets | 13.78M | 6.86M | 321,212 | 17.93M | 118.06M | 117.59M |
| Total Debt | 6,764 | 22,555 | 47,576 | 0 | 0 | 0 |
| Cash & Equiv | 6.01M | 3.13M | 87,098 | 14,129 | 5,403 | 693,818 |
| Book Value | (2.86M) | 6.59M | 22,994 | 11.20M | 108.96M | 99.78M |
| Return on Equity | N/A | -0.21 | 0.59 | 0.34 | 0.08 | -0.03 |
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (2.21M) | (3.37M) | 417,791 | 2.19M | 17.10M | (22.02M) | 692,044 |
| EPS | -0.65 | -0.98 | 0.10 | 0.54 | 4.05 | -5.12 | 0.16 |
| Free Cash Flow | (298,190) | (490,410) | (365,650) | (21,570) | (592,520) | (629,740) | (688,420) |
| FCF / Share | -0.09 | -0.14 | -0.09 | -0.01 | -0.14 | -0.15 | -0.16 |
| Operating CF | (298,190) | (490,407) | (365,649) | (21,568) | (592,517) | (629,741) | (688,422) |
| Total Assets | 2.95M | 3.52M | 6.86M | 10.77M | 10.69M | 13.51M | 13.24M |
| Total Debt | 0 | 0 | 22,555 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 6,312 | 403 | 3.13M | 2 | 39,970 | 4,487 | 4,228 |
| Book Value | (16.05M) | (13.25M) | 6.59M | (2.87M) | (5.06M) | (19.05M) | 2.97M |
| Return on Equity | N/A | N/A | 0.06 | N/A | N/A | N/A | 0.23 |
YDES News
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio Limited Reports Full Year 2025 Financial Results
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem